Anlon Healthcare has successfully concluded its board meeting on March 6, 2026, approving comprehensive corporate restructuring measures including a 1:5 stock split and 1:1 bonus share issuance. The board meeting, held at the company's registered office, commenced at 12:00 p.m. IST and concluded at 01:00 p.m. IST.

Board Approved Corporate Actions

The company has formalized its capital restructuring plan with specific implementation details that will significantly impact shareholders and enhance market accessibility. The proposed corporate actions are aimed at enhancing liquidity of the company's equity shares and enabling higher participation from public shareholders.

Stock Split Implementation Details

The approved 1:5 stock split will subdivide each existing equity share having face value of Rs.10 into 5 equity shares with face value of Rs.2 each. The current paid-up capital of Rs.53,15,15,000 comprising 5,31,51,500 shares will transform into 26,57,57,500 shares post-subdivision, maintaining the same total capital value.

Bonus Share Allocation

The board has approved issuing bonus equity shares in a 1:1 ratio, meaning shareholders will receive 1 bonus equity share of Rs.2 each for every 1 equity share held as on the record date. The bonus issue will utilize Rs.53,15,15,000 from the company's free reserves, which stood at Rs.147.08 crore as on December 31, 2025.

Capital Structure Post Implementation

Following the completion of both corporate actions, the company's authorized share capital will increase to Rs.1,10,00,00,000, divided into 55,00,00,000 equity shares of Rs.2 each. The paid-up capital will double to Rs.1,06,30,30,000 comprising 53,15,15,000 equity shares.

Regulatory Compliance and Next Steps

The company has appointed M/s. K.P. Ghelani & Associates, Practicing Company Secretaries, as scrutinizer for conducting the postal ballot and e-voting process. The board has also approved the postal ballot notice for seeking member approval and other statutory requirements. All corporate actions are subject to member approval and completion of applicable statutory requirements within the estimated 2-month timeline.

Anlon Healthcare Limited has extended the timeline for completing its acquisition of Bizotic Life Science Private Limited, citing pending procedural requirements. The company notified both BSE and NSE on February 27, 2026, regarding this significant development in its acquisition strategy.

Amendment to Share Purchase Agreement

The pharmaceutical company has entered into an amendment agreement dated February 27, 2026, modifying the terms of the original Share Purchase Agreement executed on November 28, 2025. The amendment specifically addresses the timeline for completing the acquisition process.

Acquisition Details

The Share Purchase Agreement involves Anlon Healthcare Limited acquiring a majority stake of 56.67% in Bizotic Life Science Private Limited. This acquisition represents a strategic move by Anlon Healthcare to expand its presence in the life sciences sector through the target company.

The original timeline established in November 2025 has proven insufficient due to various procedural requirements that remain pending. These requirements are typical in corporate acquisitions and often involve regulatory approvals, due diligence processes, and compliance procedures.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30(7) of the SEBI Listing Obligations and Disclosures Requirements Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about material events and developments that could impact investor decisions.

The notification was signed by Punitkumar Rasadia, Managing Director of Anlon Healthcare Limited, ensuring proper authorization and compliance with corporate governance requirements. The extended timeline of 125 days from the original execution date provides the parties with additional time to complete all necessary procedural formalities for the successful completion of this acquisition.